ARTICLE | Clinical News

Enbrel etanercept regulatory update

August 30, 2010 7:00 AM UTC

The U.K.'s NICE issued guidance reiterated its final appraisal determinations (FAD) from earlier this year recommending use of 5 drugs to treat severe active rheumatoid arthritis (RA) in patients who had an inadequate response to, or are intolerant of, other DMARDs, including at least one TNF inhibitor. The agency recommended in favor of MabThera rituximab from Roche in combination with methotrexate, and also backed Humira adalimumab, Enbrel etanercept, Remicade infliximab and Orencia abatacept in combination with methotrexate in patients unable to receive MabThera. NICE issued the FADs earlier this year (see BioCentury, June 28 & July 5). ...